A case of refractory palmoplantar psoriasis treated with tildrakizumab

Ital J Dermatol Venerol. 2022 Aug;157(4):379-380. doi: 10.23736/S2784-8671.21.07148-6.

Authors

Alessio Gambardella¹, Gaetano Licata², Vittorio Tancredi¹, Giulia Calabrese¹, Alina DE Rosa¹, Roberto Alfano³, Giuseppe Argenziano¹

Affiliations

¹ Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples, Italy.
² Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples, Italy - [email protected].
³ Department of Anesthesiology, Surgery and Emergency, Luigi Vanvitelli University of Campania, Naples, Italy.

PMID: 35916185
DOI: 10.23736/S2784-8671.21.07148-6

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Psoriasis* / complications

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab